1. Home
  2. VGI vs MXCT Comparison

VGI vs MXCT Comparison

Compare VGI & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virtus Global Multi-Sector Income Fund of Beneficial Interest

VGI

Virtus Global Multi-Sector Income Fund of Beneficial Interest

HOLD

Current Price

$7.43

Market Cap

83.1M

Sector

Finance

ML Signal

HOLD

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

HOLD

Current Price

$1.07

Market Cap

93.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VGI
MXCT
Founded
2012
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.1M
93.0M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
VGI
MXCT
Price
$7.43
$1.07
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$5.50
AVG Volume (30 Days)
37.7K
1.0M
Earning Date
01-01-0001
05-12-2026
Dividend Yield
12.66%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$33,026,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$18.50
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.20
$0.64
52 Week High
$8.09
$2.40

Technical Indicators

Market Signals
Indicator
VGI
MXCT
Relative Strength Index (RSI) 47.25 63.33
Support Level $7.23 $0.77
Resistance Level $7.98 $1.16
Average True Range (ATR) 0.09 0.08
MACD -0.00 0.01
Stochastic Oscillator 46.67 76.06

Price Performance

Historical Comparison
VGI
MXCT

About VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest

Virtus Global Multi-Sector Inc is a United States based fund. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objective by applying extensive credit research to capitalize on opportunities across undervalued areas of the international bond markets.

About MXCT MaxCyte Inc.

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

Share on Social Networks: